نتایج جستجو برای: everolimus

تعداد نتایج: 3889  

Journal: :international journal of epidemiology research 0
morteza arab zozani iranian center of excellence in health management, tabriz university of medical sciences, tabriz, i.r. iran mitra mahdavi-mazdeh iranian tissue bank and research center, tehran university of medical sciences, tehran, i.r. iran sayed alireza hosseini committee of clinical research, food and drug administration, tehran, i.r. iran reza majdzadeh school of public health and knowledge utilization research center, tehran university of medical sciences, tehran, i.r. iran ali akbari sari health management and economics dept., tehran university of medical sciences, tehran, i.r. iran

background and aims: immunosuppressive regimens are a key component for successful kidney transplantation. this systematic review aimed to assess the efficacy and safety of combination therapy of everolimus with tacrolimus in kidney transplantation recipients. methods: results were limited to english-language articles. trials where recipients received another regimen were excluded. the cochrane...

Background and aims: Immunosuppressive regimens are a key component for successful kidney transplantation. This systematic review aimed to assess the efficacy and safety of combination therapy of everolimus with tacrolimus in kidney transplantation recipients. Methods: Results were limited to English-language articles. Trials where recipients received ano...

اکبری ساری, علی, حسینی, سید علیرضا , عرب زوزنی, مرتضی , مجدزاده, سید رضا , مهدوی مزده, میترا , ولایتی, اشرف ,

Background: Everolimus is an immunosuppressive agent with a novel mode of action but has a different clinical role with calcineurin inhibitors (CNI). The aim of this study was to evaluate the safety and effectiveness of everolimus compared with sirolimus and tacrolimus in preventing kidney transplantation rejection. Methods: Search was conducted for finding randomized clinical trials (RCT) unt...

2016
Lucia Raimondo Valentina D'Amato Alberto Servetto Roberta Rosa Roberta Marciano Luigi Formisano Concetta Di Mauro Roberta Clara Orsini Priscilla Cascetta Paola Ciciola Ana Paula De Maio Maria Flavia Di Renzo Sandro Cosconati Agostino Bruno Antonio Randazzo Filomena Napolitano Nunzia Montuori Bianca Maria Veneziani Sabino De Placido Roberto Bianco

Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellular functions. Although mTOR inhibitors have significantly improved survival of different cancer p...

Journal: :Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006
Gary Levy Heinz Schmidli Jeffrey Punch Elizabeth Tuttle-Newhall David Mayer Peter Neuhaus Didier Samuel Bjorn Nashan Juergen Klempnauer Alan Langnas Yvon Calmus Xavier Rogiers Michael Abecassis Richard Freeman Maarten Sloof John Roberts Lutz Fischer

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 groups: everolimus 0.5 mg bid, everolimus 1.0 mg bid, everolimus 2 mg bid, or placebo. Patients recei...

2012
Aldo M. Roccaro Antonio Sacco Xiaojing Jia Ranjit Banwait Patricia Maiso Feda Azab Ludmila Flores Salomon Manier Abdel Kareem Azab Irene M. Ghobrial

Purpose: The TORC1 inhibitor everolimus has previously shown significant activity as a single agent in hematologic malignancies, with reported responses of 30% to 70% in Waldenstrom macroglobulinemia. However, the specific mechanisms by which this class of mTOR inhibitors exerts anti– Waldenstrom macroglobulinemia activity have not been fully investigated. We therefore sought to dissect the mec...

Journal: :Oncology reports 2012
Helena J Mauceri Harold G Sutton Thomas E Darga Masha Kocherginsky Joel Kochanski Ralph R Weichselbaum Everett E Vokes

Signaling pathways that activate mTOR (mammalian target of rapamycin) are altered in many human cancers and these alterations are associated with prognosis and treatment response. mTOR inhibition can restore sensitivity to DNA damaging agents such as cisplatin. The rapamycin derivative everolimus exhibits antitumor activity and is approved for pat...

Journal: :The oncologist 2014
Robert Wesolowski Mahmoud Abdel-Rasoul Maryam Lustberg Maria Paskell Charles L Shapiro Erin R Macrae

INTRODUCTION The overall incidence and odds of fatal adverse events (FAEs) after exposure to everolimus are not well defined. We performed a comprehensive meta-analysis of published randomized controlled trials (RCTs) to determine the role of everolimus in treatment-related mortality in patients with cancer. METHODS PubMed databases and abstracts from the proceedings of the American Society o...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Aldo M Roccaro Antonio Sacco Xiaojing Jia Ranjit Banwait Patricia Maiso Feda Azab Ludmila Flores Salomon Manier Abdel Kareem Azab Irene M Ghobrial

PURPOSE The TORC1 inhibitor everolimus has previously shown significant activity as a single agent in hematologic malignancies, with reported responses of 30% to 70% in Waldenstrom macroglobulinemia. However, the specific mechanisms by which this class of mTOR inhibitors exerts anti-Waldenstrom macroglobulinemia activity have not been fully investigated. We therefore sought to dissect the mecha...

2017
J. J. Knox C. H. Barrios T. M. Kim T. Cosgriff V. Srimuninnimit K. Pittman R. Sabbatini S. Y. Rha T. W. Flaig R. D. Page J. T. Beck F. Cheung S. Yadav P. Patel L. Geoffrois J. Niolat N. Berkowitz M. Marker D. Chen R. J. Motzer

Background RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points. Patients and methods Patients received either first-line...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید